Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10,337 | 1,249 | 8,988 | 2,474 | 1,835 |
| Other current assets | 889 | 6,914 | 57 | 0 | 8 |
| TOTAL | $11,651 | $8,944 | $9,612 | $2,664 | $1,995 |
| Non-Current Assets | |||||
| PPE Net | 43 | 88 | 88 | 7 | 2 |
| Other Non-Current Assets | 246 | 80 | 155 | 0 | 0 |
| TOTAL | $290 | $167 | $243 | $7 | $2 |
| Total Assets | $11,940 | $9,111 | $9,855 | $2,672 | $1,997 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,372 | 1,848 | 1,525 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,156 | 1,795 | 900 | 381 | 140 |
| Accrued Expenses | 1,123 | 658 | 345 | 62 | N/A |
| Other current liabilities | 7,052 | 7,724 | 886 | 300 | 831 |
| TOTAL | $13,901 | $12,119 | $3,912 | $787 | $971 |
| Non-Current Liabilities | |||||
| aiOther Non-Current Liabilities | 171 | 0 | 79 | 1,434 | 478 |
| TOTAL | $171 | $N/A | $79 | $1,434 | $478 |
| Total Liabilities | $14,072 | $12,119 | $3,991 | $2,221 | $1,449 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,063 | 3,886 | 1,984 | 1,400 | 733 |
| Common Shares | 12 | 4 | 476 | 288 | 183 |
| Retained earnings | -104,383 | -66,738 | -47,256 | -38,734 | -32,173 |
| TOTAL | $-2,132 | $-3,008 | $5,864 | $451 | $548 |
| Total Liabilities And Equity | $11,940 | $9,111 | $9,855 | $2,672 | $1,997 |